Immunohematology Market Size, Share, Growth Analysis, By Type(ABO blood grouping and Rh typing) - Industry Forecast 2024-2031

Immunohematology Market size was valued at USD 3.20 billion in 2021 and is poised to grow from USD 3.90 billion in 2022 to USD 7.86 billion by 2030, growing at a CAGR of 10.5% in the forecast period (2023-2030).

The immunohematology market is characterized by a mix of established companies and emerging players. Market participants are focusing on research and development activities to enhance the efficiency and performance of Immunohematologys. Additionally, strategic collaborations, partnerships, and mergers and acquisitions are prevalent strategies adopted by companies to expand their market presence. The competitive environment is further influenced by factors such as technological advancements, government regulations, and the ability to provide cost-effective and sustainable solutions. 'Grifols (Spain)', 'Ortho Clinical Diagnostics (United States)', 'Immucor (United States)', 'Bio-Rad Laboratories (United States)', 'Beckman Coulter (United States)', 'Novartis (Switzerland)', 'Quotient Limited (United Kingdom)', 'Diagast (France)', 'Becton, Dickinson and Company (United States)', 'Thermo Fisher Scientific (United States)', 'Abbott Laboratories (United States)', 'BioMérieux (France)', 'Hologic, Inc. (United States)', 'Immucor, Inc. (United States)', 'Merck KGaA (Germany)', 'DiaSorin S.p.A. (Italy)', 'F. Hoffmann-La Roche AG (Switzerland)', 'mmucor Gamma Biologics (United States)', 'Tulip Diagnostics Pvt. Ltd. (India)', 'Ortho Clinical Diagnostics (Belgium)'

One driver of the immunohematology market is the increasing demand for blood transfusion services. With the rising prevalence of chronic diseases, surgical procedures, and trauma cases, there is a growing need for safe and compatible blood products for transfusion. Immunohematology plays a crucial role in ensuring the compatibility of blood products with the recipient's blood type, reducing the risk of adverse reactions and improving patient outcomes. This drives the adoption of immunohematology testing and related products in healthcare settings.

One key market trend in the immunohematology market is the increasing adoption of automated and integrated systems for blood typing and cross-matching. With advancements in technology, there is a growing demand for efficient and accurate immunohematology testing methods. Automated systems offer benefits such as reduced human errors, improved workflow efficiency, and faster turnaround time for test results. These systems integrate various processes, including sample preparation, antibody identification, and data analysis, into a single platform, enhancing laboratory productivity. Furthermore, the integration of immunohematology systems with laboratory information management systems (LIMS) allows for seamless data management and improved traceability. The shift towards automation and integration in immunohematology is driven by the need for enhanced patient safety, increased efficiency, and improved laboratory performance.

One dominant region in the immunohematology market is North America. This region has a well-established healthcare infrastructure and a high demand for blood products due to a large population and a significant number of medical procedures. The presence of key market players, technological advancements, and government initiatives promoting safe blood transfusion practices contribute to the dominance of North America in the Immunohematology market.